CHICAGO MEDICAL RESEARCH, LLC.

Name: Wahid Kassar, MD, FACE

Email: kassar@cmrllc1.com

PROFESSIONAL EMPLOYMENT:

July 2025 - Present	Associate Director, Chicago Medical Research - HC, Hazel Crest, Illinois
July 2025 - Present	Associate Director, Chicago Medical Research - WR, Woodridge, Illinois
November 2021 - Present	Medical Director, Diabetes Center, Silver Cross Hospital, New Lenox, Illinois
July 2020 - Present	Private Practice, Elite Endocrinology, Chicago, Illinois
June 2006 - Present	Faculty International Speaker, Keynote Speaker, and Premier Lecturer, CME presentations in diabetes and obesity: Beirut, Lebanon (2017); Dubai, UAE and Muscat, Oman (2015); Istanbul, Turkey (2014); Vienna, Austria (2013); Antalya, Turkey (2007); Riyadh, Saudi Arabia (2005); and Damascus, Syria (2002).
October 2013 - Present	Board Member, Quality Improvement and Patient Safety Council, Central DuPage Hospital / Cadence Health System
October 2018 - October 2020	President, American Association of Clinical Endocrinologists, Illinois Chapter
June 2003 - June 2020	Consultant Endocrinologist, Central DuPage Hospital, Northwestern Medicine Health System / West Region
2003 - 2020	Medical Advisor, The Diabetes Center
July 2018 - July 2019	Physician Lead, Department of Endocrinology
2013 - 2019	Medical Advisor, Bone Health Clinic
2011 - 2017	Medical Advisor, The Bariatric Center
July 2011 - June 2017	Board Member, NAAMA (National Arab American Medical Association)
April 1999 - September 2002	Consultant Endocrinologist, The Consulting Clinics / Kingdom Hospital, Riyadh, Kingdom of Saudi Arabia
April 1998 - April 1999	Consultant Endocrinologist, Premiere Physicians Group, Westlake, Ohio
March 1997 - March 1998	Medical Intensivist, Southwest General Hospital, Middleburg Heights, Ohio
February 1996 - February 1997	Consultant, Private Practice, Endocrinology / Internal Medicine, Lorain, Ohio

October 1995 - April 1998	House Physician, St. John West Shore Hospital, Westlake, Ohio
January 1988 - March 1988	House Physician, Hamode Hospital, Damascus, Syria
	National Advisory Board: Novo Nordisk and AstraZeneca
	Lecturer / Speaker Bureau: Abbott, Mankind, Bayer, Lilly, Boehringer Ingelheim, Novo Nordisk, Sanofi, Merck, GSK, Johnson & Johnson, Takeda, and AstraZeneca
	Adjunct Faculty Educator for medical students and nurse practitioners: Loyola University Chicago; University of Illinois Chicago; University of St. Francis; and Lewis University

EDUCATION:

August 1995 - September 1995	Externship, Pediatric Endocrinology, Cleveland Clinic Foundation, Cleveland, Ohio
1993 - 1995	Fellowship, Endocrinology and Metabolism, Cleveland Clinic Foundation, Cleveland, Ohio
1990 - 1993	Internal Medicine Residency Training Program, PGY 1-3, St. Barnabas Hospital, Bronx, New York
1986	Trainee, Private Surgical Clinic, Damascus, Syria
1985	Externship, Clinical Cardiology, University of London, Royal Postgraduate Medical School, London, England
1981 - 1987	Doctor of Medicine, University of Damascus, Damascus, Syria

LICENSE: State of Illinois - 036.107989

CERTIFICATIONS AND EXAMINATIONS:

- American Board of Endocrinology - 1997
- American Board of Internal Medicine - 1994
- F.L.E.X.: Part I, 1989; Part II, 1992
- E.C.F.M.G.: Parts I and II, 1989

THERAPEUTIC AREA OF EXPERTISE:

Therapeutic Area	Sub-Therapeutic Area
Endocrinology	Diabetes Mellitus Type II
Nephrology	Chronic Kidney Disease
Cardiology	Hypertension

ORGANIZATIONS AND MEMBERSHIP:

- American Diabetes Association
- American Association of Clinical Endocrinology
- Endocrine Society

PUBLICATIONS AND RESEARCH:

1. The Relation Between Glucose Control and Sternal Wound Infections in Patients With CABG. Supervised by Dr. Byron Hoogwerf, Director of Endocrine Fellowship, Cleveland Clinic Foundation, Ohio. Accepted to the ADA Meeting, Atlanta, Georgia, 1996.

2. Comparing PTH Levels in Patients With Renal Failure Versus Patients With Hyperparathyroidism. Supervised by Dr. Angelo Licata, Cleveland Clinic Foundation, Ohio, 1996.
3. Case Report: GH-Secreting Pituitary Carcinoma. Supervised by Dr. Leslie Sheeler, Cleveland Clinic Foundation, Ohio, 1994.
4. Study of AccuChek Accuracy in the Inpatient Setting. Supervised by Dr. James Hellerman, Chief of Endocrinology and Director of the Internal Medicine Residency Program, St. Barnabas Hospital, New York, 1993.
5. Study of the Protective Effects of Ascorbic Acid on Brain Tissue Against Oxygen-Radical Damage After Trauma. Department of Pharmacology and Toxicology, Dr. Paul Sato, Michigan State University, East Lansing, Michigan.
6. Study in Public Health About the Distribution of Tuberculosis in Northeastern Syria. University of Damascus, 1989.

CLINICAL TRIAL EXPERIENCE

1. **Protocol: 20230227 (MARITIME-HF)** - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity.
2. **Protocol: NN9490-8266 (POLARIS)** - Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).
3. **Protocol: 1378-0020 (EASi-HF Preserved)** - A Phase III Double-Blind, Randomised, Parallel-Group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Symptomatic Heart Failure (HF: NYHA II-IV) and Left Ventricular Ejection Fraction (LVEF) >=40%.
4. **Protocol: ALN-AGT01-008 (ZENITH)** - A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease.
5. **Protocol: NN9490-8665 (AMBITION)** - Efficacy and safety of zenagamtide s.c. once weekly compared to insulin glargine s.c. once daily in participants with type 2 diabetes and increased cardiovascular risk inadequately controlled on 1-3 oral glucose-lowering medications (AMBITION 7).
6. **Protocol: C4291003 (BRANCH-HF)** - A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Oral Branched Chain Ketoacid Dehydrogenase Kinase Inhibitor, PF-07328948, in Adults With Heart Failure.

SIGNATURE & DATE:

Signed by Wahid Kassar, MD, FACE

Wahid Kassar, MD, FACE | I approve this document 22-Jul-2026 | 3:37:14 PM CDT 22-Jul-2026

7F9AE4C7C8C54307809238A5714009F3